BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 12678910)

  • 1. Chemical and biological profile of dual Cdk1 and Cdk2 inhibitors.
    Ruetz S; Fabbro D; Zimmermann J; Meyer T; Gray N
    Curr Med Chem Anticancer Agents; 2003 Jan; 3(1):1-14. PubMed ID: 12678910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
    Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
    Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.
    Arris CE; Boyle FT; Calvert AH; Curtin NJ; Endicott JA; Garman EF; Gibson AE; Golding BT; Grant S; Griffin RJ; Jewsbury P; Johnson LN; Lawrie AM; Newell DR; Noble ME; Sausville EA; Schultz R; Yu W
    J Med Chem; 2000 Jul; 43(15):2797-804. PubMed ID: 10956187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors.
    Legraverend M; Ludwig O; Bisagni E; Leclerc S; Meijer L; Giocanti N; Sadri R; Favaudon V
    Bioorg Med Chem; 1999 Jul; 7(7):1281-93. PubMed ID: 10465404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells.
    Iseki H; Ko TC; Xue XY; Seapan A; Hellmich MR; Townsend CM
    Surgery; 1997 Aug; 122(2):187-94; discussion 194-5. PubMed ID: 9288122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.
    Mettey Y; Gompel M; Thomas V; Garnier M; Leost M; Ceballos-Picot I; Noble M; Endicott J; Vierfond JM; Meijer L
    J Med Chem; 2003 Jan; 46(2):222-36. PubMed ID: 12519061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
    David-Pfeuty T
    Oncogene; 1999 Dec; 18(52):7409-22. PubMed ID: 10602500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor.
    Davies TG; Bentley J; Arris CE; Boyle FT; Curtin NJ; Endicott JA; Gibson AE; Golding BT; Griffin RJ; Hardcastle IR; Jewsbury P; Johnson LN; Mesguiche V; Newell DR; Noble ME; Tucker JA; Wang L; Whitfield HJ
    Nat Struct Biol; 2002 Oct; 9(10):745-9. PubMed ID: 12244298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus-mediated E2F-1 gene transfer induces an apoptotic response in human gastric carcinoma cells that is enhanced by cyclin dependent kinase inhibitors.
    Atienza C; Elliott MJ; Dong YB; Yang HL; Stilwell A; Liu TJ; McMasters KM
    Int J Mol Med; 2000 Jul; 6(1):55-63. PubMed ID: 10851267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2.
    Mesguiche V; Parsons RJ; Arris CE; Bentley J; Boyle FT; Curtin NJ; Davies TG; Endicott JA; Gibson AE; Golding BT; Griffin RJ; Jewsbury P; Johnson LN; Newell DR; Noble ME; Wang LZ; Hardcastle IR
    Bioorg Med Chem Lett; 2003 Jan; 13(2):217-22. PubMed ID: 12482427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity.
    Alessi F; Quarta S; Savio M; Riva F; Rossi L; Stivala LA; Scovassi AI; Meijer L; Prosperi E
    Exp Cell Res; 1998 Nov; 245(1):8-18. PubMed ID: 9828096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design of potent CDK1 inhibitors derived from olomoucine.
    Furet P; Zimmermann J; Capraro HG; Meyer T; Imbach P
    J Comput Aided Mol Des; 2000 Jul; 14(5):403-9. PubMed ID: 10896313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases.
    Misra RN; Rawlins DB; Xiao HY; Shan W; Bursuker I; Kellar KA; Mulheron JG; Sack JS; Tokarski JS; Kimball SD; Webster KR
    Bioorg Med Chem Lett; 2003 Mar; 13(6):1133-6. PubMed ID: 12643928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases.
    Hirai H; Kawanishi N; Iwasawa Y
    Curr Top Med Chem; 2005; 5(2):167-79. PubMed ID: 15853645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2.
    Otyepka M; Krystof V; Havlícek L; Siglerová V; Strnad M; Koca J
    J Med Chem; 2000 Jun; 43(13):2506-13. PubMed ID: 10891109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiproliferative effect of plant cytokinin analogues with an inhibitory activity on cyclin-dependent kinases.
    Vermeulen K; Strnad M; Krystof V; Havlícek L; Van der Aa A; Lenjou M; Nijs G; Rodrigus I; Stockman B; van Onckelen H; Van Bockstaele DR; Berneman ZN
    Leukemia; 2002 Mar; 16(3):299-305. PubMed ID: 11896531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects.
    Kim KS; Sack JS; Tokarski JS; Qian L; Chao ST; Leith L; Kelly YF; Misra RN; Hunt JT; Kimball SD; Humphreys WG; Wautlet BS; Mulheron JG; Webster KR
    J Med Chem; 2000 Nov; 43(22):4126-34. PubMed ID: 11063609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.
    De Azevedo WF; Leclerc S; Meijer L; Havlicek L; Strnad M; Kim SH
    Eur J Biochem; 1997 Jan; 243(1-2):518-26. PubMed ID: 9030780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delta MEKK3:ER* activation induces a p38 alpha/beta 2-dependent cell cycle arrest at the G2 checkpoint.
    Garner AP; Weston CR; Todd DE; Balmanno K; Cook SJ
    Oncogene; 2002 Nov; 21(53):8089-104. PubMed ID: 12444545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of cylin-dependent kinase 1 inhibitors of a new chemical type by structure-based design and database searching.
    Furet P; Meyer T; Mittl P; Fretz H
    J Comput Aided Mol Des; 2001 May; 15(5):489-95. PubMed ID: 11394741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.